

**NOTICE OF INTENT**  
**Office of the Governor**  
**Division of Administration**  
**Racing Commission**

The Louisiana State Racing Commission hereby gives notice that it intends to discuss and/or amend the following rule. Pursuant to Thoroughbred Owners and Breeders Association (TOBA) and the American Graded Stakes Committee, as of January 2013, in order to retain a listed race's status, the horses participating in such race shall be subject to the same testing requirements that are currently in place as to non-steroidal anti-inflammatory drugs, which are provided below.

This proposed rule has no known impact on family formation, stability, and/or autonomy as described in R.S. 49:972.

**Title 35**  
**HORSE RACING**  
**Part I. General Provisions**  
**Chapter 15. Permitted Medication**

**§1505. Nonsteroidal and/or Anti-Inflammatory Medication**

- A. ...
- B. ...
- C. For all horses entered in a graded or listed stakes race, the maximum analytical test result levels of the blood of such horse, regardless of time of administration, shall be as follows.

Post-Race Blood Level	Total of Drug and/or Metabolite
Phenylbutazone	2.0 micrograms per milliliter

AUTHORITYNOTE: Promulgated in accordance with R.S. 4:141 and R.S. 4:142.

HISTORICAL NOTE: Promulgated by the Department of Commerce, Racing Commission, LR 9:547 (August 1983), amended by the Office of the Governor, Division of Administration, Racing Commission, LR 38:1408 (June 2012).